@article {742,
	title = {Vanadyl-thiazolidinedione combination agents for diabetes therapy},
	journal = {Bioconjugate Chemistry},
	volume = {14},
	number = {1},
	year = {2003},
	note = {ISI Document Delivery No.: 637YYTimes Cited: 23Cited Reference Count: 42},
	month = {Jan-Feb},
	pages = {212-221},
	type = {Article},
	abstract = {A series of vanadium compounds, chelated by ligands containing a thiazolidinedione moiety as an additional insulin-enhancing component, were produced in this study to create potentially synergistic compounds. A set of four bifunctional ligand precursors were synthesized: (+/-)-5-4-[(5-hydroxy-4-oxo-4H-pyran-2-ylmethyl)amino]benzylthiazolidi ne-2,4-dione (HL1), (+/-)-5-4-[5-hydroxy-1-methyl-4-oxo-1,4-dihydro-pyridin-2-ylmethyl)amin o]benzylthiazolidine-2,4-dione (HL2) 5-[4-(5-hydroxy-4-oxo-4H-pyran-2-ylmethoxy)benzylidenelthiazolidine-2,4- dione (HL1), and (+/-)-5-4-(5-hydroxy-4-oxo-4H-pyran-2-ylmethoxy)benzyl]thiazolidine-2,4 -dione (HL4), each containing a metal chelating portion as well as a thiazolidinedione moiety. From this set of ligand precursors, air-stable VO(L-1)(2), VO(L-3)(2), and VO(L-4)(2) were prepared. The four ligand precursors and three complexes were tested for insulin-enhancing potential in STZ-diabetic rats and compared to rosiglitazone and BMOV, respectively. Both the ligand precursors HL1 and HL3 showed enhanced activity compared with that of rosiglitazone. The complex VO(L-3)(2) showed the most efficacious hypoglycemic effects in this study; however, neither additive nor synergistic effects were observed using this acute animal model.},
	keywords = {AGENT, ANTIHYPERGLYCEMIC, BIOLOGICAL-ACTIVITY, BIS(MALTOLATO)OXOVANADIUM(IV), BLOOD-GLUCOSE, COMPLEXES, DERIVATIVES, GLUCOSE-LOWERING PROPERTIES, INSULIN MIMETIC AGENT, RAT ADIPOCYTES, TROGLITAZONE},
	isbn = {1043-1802},
	url = {<Go to ISI>://000180542400025},
	author = {Storr, T. and Mitchell, D. and Buglyo, P. and Thompson, K. H. and Yuen, V. G. and McNeill, J. H. and Orvig, Chris}
}
@article {508,
	title = {Reduction of [VO2(ma)(2)](-) and [VO2(ema)(2)](-) by ascorbic acid and glutathione: Kinetic studies of pro-drugs for the enhancement of insulin action},
	journal = {Inorganic Chemistry},
	volume = {41},
	number = {6},
	year = {2002},
	note = {ISI Document Delivery No.: 532TZTimes Cited: 38Cited Reference Count: 31},
	month = {Mar},
	pages = {1357-1364},
	type = {Article},
	abstract = {{To shed light on the role of V(V) complexes as pro-drugs for theirV(IV) analogues, the kinetics of the reduction reactions of [VO2(ma)(2)](-) or [VO2(ema)(2)](-) (Hma = maltol},
	keywords = {AGENT BIS(MALTOLATO)OXOVANADIUM(IV) BMOV, CHEMISTRY, COMPLEXES, DIABETIC RATS, GLUCOSE-LOWERING PROPERTIES, LIGANDS, MIMETIC AGENT, SULFATE, VANADATE, VANADIUM COMPOUNDS},
	isbn = {0020-1669},
	url = {<Go to ISI>://000174492300008},
	author = {Song, B. and Aebischer, N. and Orvig, Chris}
}
@article {4706,
	title = {Vanadyl-biguanide complexes as potential synergistic insulin mimics},
	journal = {Journal of Inorganic Biochemistry},
	volume = {76},
	number = {3-4},
	year = {1999},
	note = {ISI Document Delivery No.: 262ZHTimes Cited: 65Cited Reference Count: 27},
	month = {Sep},
	pages = {251-257},
	type = {Article},
	abstract = {Vanadium has well-documented blood-glucose-lowering properties both in vitro and in vivo. The design of new oxovanadium(IV) coordination compounds, intended for use as insulin-enhancing agents in the treatment of diabetes mellitus, can potentially benefit from a synergistic approach, in which the whole complex has more than an additive effect from its component parts. Biguanides, most importantly metformin, are oral hypoglycemic agents used today to treat type 2 diabetes mellitus. In this study, biguanide, metformin, and phenformin, all biguanides, were coordinated to oxovanadium(IV) to form potential insulin-enhancing compounds. Highly colored, air-stable, bis(biguanidato)oxovanadium(IV), [VO(big)(2)], bis(N{\textquoteright},N{\textquoteright}-dimethylbiguanidato)oxovanadium(IV) [VO(metf)(2)], and bis(beta-phenethyl-biguanidato)oxovanadium(IV), [VO(phenf)(2)], were prepared. Solvation with dimethylsulfoxide occurred with VO(metf)(2) to form a six-coordinate complex. Precursor ligands and oxovanadium(IV) coordination complexes were characterized by infrared spectroscopy, mass spectrometry, elemental analyses, magnetic susceptibility, and, where appropriate, H-1 NMR spectroscopy. Biological testing with VO(metf)(2), a representative compound, for insulin-enhancing potential included acute (72 h) administration, both by intraperitoneal (i.p.) injection and by oral gavage (p.o,) in streptozotocin (STZ)-diabetic rats. VO(metf)(2) administration resulted in significant blood-glucose lowering at doses of 0.12 mmol kg(-1) i.p. and 0.60 mmol kg(-1) p.o. (previously established as ED50 doses for organically chelated oxovanadium(IV) complexes); however, no positive associative effects due to the presence of biguanide in the complex were apparent. (C) 1999 Elsevier Science Inc. All rights reserved.},
	keywords = {biguanide, BIS(MALTOLATO)OXOVANADIUM(IV), BMOV, coordination complex, GLUCOSE-LOWERING PROPERTIES, insulin mimic, MECHANISM, METFORMIN, MIMETIC AGENT, MUSCLE, RATS, VANADIUM},
	isbn = {0162-0134},
	url = {<Go to ISI>://000084097800010},
	author = {Woo, L. C. Y. and Yuen, V. G. and Thompson, K. H. and McNeill, J. H. and Orvig, Chris}
}
